13 October 2023: Clinical Research
Rising Drug Resistance Among Gram-Negative Pathogens in Bloodstream Infections: A Multicenter Study in Ulanhot, Inner Mongolia (2017–2021)
Yinxia Feng 1AE* , Zhijun Wang 1B* , Zelin Hao 2C , Jinlong Du 3D , Hui Jiang 1F*DOI: 10.12659/MSM.940686
Med Sci Monit 2023; 29:e940686
Table 5 Resistance rates of Escherichia coli to antibiotics.
| Anti-bacterial agent | 2017 (n=164) | 2018 (n=186) | 2019 (n=201) | 2020 (n=134) | 2021 (n=193) | χ2 | P value |
|---|---|---|---|---|---|---|---|
| Piperacillin | 55.68 | 61.14 | 65.25 | 72.97 | 67.56 | 11.680 | 0.002 |
| Ciprofloxacin | 58.55 | 58.61 | 61.37 | 61.64 | 60.1 | 0.628 | 0.960 |
| Levofloxacin | 56.49 | 55.66 | 58.96 | 58.85 | 55.64 | 0.884 | 0.927 |
| Compound sulfamethoxazole | 55.41 | 59.45 | 57.24 | 54.46 | 50.87 | 3.352 | 0.501 |
| Cefazolin | 46.85 | 45.13 | 41.52 | 47.34 | 43.68 | 1.686 | 0.793 |
| Amoxicillin/clavulanic acid | 36.52 | 58.22 | 46.84 | 38.28 | 34.66 | 27.806 | |
| Cefuroxime | 42.57 | 42.57 | 39.52 | 46.15 | 41.95 | 1.625 | 0.804 |
| Gentamicin | 40.12 | 34.48 | 37.16 | 35.53 | 37.95 | 1.412 | 0.842 |
| Ampicillin/sulbactam | 22.13 | 27.35 | 34.48 | 42.96 | 33.94 | 18.201 | 0.001 |
| Aztreonam | 26.14 | 26.87 | 24.64 | 27.55 | 23.69 | 0.838 | 0.933 |
| Cefepime | 28.45 | 28.33 | 16.54 | 13.41 | 10.33 | 33.004 | |
| Minocycline | 16.32 | 21.84 | 14.67 | 15.73 | 16.41 | 4.498 | 0.343 |
| Ceftazidime | 13.88 | 15.62 | 15.45 | 20.42 | 14.55 | 2.570 | 0.632 |
| Cefoxitin | 9.23 | 6.43 | 7.18 | 9.44 | 8.74 | 1.862 | 0.761 |
| Amikacin | 2.05 | 4.91 | 1.53 | 2.56 | 1.36 | 5.113 | 0.260 |
| Cefoperazone/sulbactam | 2.37 | 2.44 | 2.54 | 2.42 | 2.67 | 0.221 | 1.000 |
| Piperacillin/tazobactam | 1.36 | 1.15 | 1.56 | 1.53 | 1.24 | 0.627 | 1.000 |
| Meropenem | 0.51 | 0.35 | 0.85 | 0.97 | 0.35 | 0.957 | 1.000 |
| Imipenem | 0.54 | 0.32 | 0.76 | 0.94 | 0.39 | 0.957 | 1.000 |
| Ceftriaxone | 39.56 | 41.59 | 39.33 | 44.71 | 42.13 | 1.221 | 0.875 |
| Data are presented as percentage rate (%). | |||||||